Preference for pharmaceutical formulation and treatment process attributes

Preference for pharmaceutical formulation and treatment process attributes

Katie D Stewart,1 Joseph A Johnston,2 Louis S Matza,1 Sarah E Curtis,2 Henry A Havel,3 Stephanie A Sweetana,3 Heather L Gelhorn1 1Outcomes Research, Evidera, Bethesda, MD, USA; 2Global Patient Outcomes & Real World Evidence, 3Small Molecule Design and Development, Eli Lilly & Compan...

Full description

Bibliographic Details
Main Authors: Stewart KD, Johnston JA, Matza LS, Curtis SE, Havel HA, Sweetana SA, Gelhorn HL
Format: Article
Language:English
Published: Dove Medical Press 2016-07-01
Series:Patient Preference and Adherence
Subjects:
Preference
treatment process
pharmaceutical formulation
conjoint
utility
contingent valuation
Online Access:https://www.dovepress.com/preference-for-pharmaceutical-formulation-and-treatment-process-attrib-peer-reviewed-article-PPA

Internet

https://www.dovepress.com/preference-for-pharmaceutical-formulation-and-treatment-process-attrib-peer-reviewed-article-PPA

Similar Items